Pennsylvania SB826 requires clinical laboratories to inform health care practitioners about the variability and potential inaccuracies of Lyme.
Pennsylvania SB826 amends the Patient Test Result Information Act to include a new section on Lyme disease testing disclosure. When a clinical laboratory reports a Lyme disease test result, it must inform the health care practitioner that Lyme disease tests can vary and may not be accurate. The practitioner must then inform the patient of this variability and advise them to consult their provider if symptoms persist, potentially for retesting and alternative treatments. This act does not relieve practitioners from existing professional obligations.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.